Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BridgeBio Pharma ( (BBIO) ) has provided an update.
BridgeBio Pharma announced significant commercial progress with its FDA-approved drug Attruby, receiving 430 prescriptions from 248 physicians, signaling strong market uptake. Additionally, the company has fully enrolled three major Phase 3 clinical trials and is well-funded, with $406 million in cash and anticipated regulatory milestone payments, positioning it to advance its late-stage pipeline programs and achieve several 2025 milestones.
More about BridgeBio Pharma
BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing and delivering transformative medicines for genetic diseases. Founded in 2015, it has a diverse pipeline ranging from early science to advanced clinical trials, emphasizing the rapid application of genetic medicine.
YTD Price Performance: 3.12%
Average Trading Volume: 1,941,752
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.5B
See more insights into BBIO stock on TipRanks’ Stock Analysis page.